Brandenburg Kapital - News about 4TEEN4 Pharmaceuticals GmbH
4TEEN4 strengthens clinical development of novel shock therapy with expanded financing
Potsdam, November 2025 - 4TEEN4 Pharmaceuticals has successfully extended its Series C financing round, securing a total of €55 million to advance the development of its next-generation shock therapy procizumab. The round was supported by several new institutional investors, along with existing backers who increased their commitments.
Procizumab is a first-in-class monoclonal antibody designed to neutralize cDPP3, a key pathological driver of cardiogenic shock and a known contributor to multi-organ failure. With the new funding, 4TEEN4 will expand its ongoing Phase 2a clinical trial, increase the number of study sites across Europe, and prepare for its planned U.S. expansion. This positions the company to achieve critical milestones on the path to the first cause-targeted shock therapy.
The financing was supported by institutional investors, family offices, and private co-investors.
Brandenburg Kapital has supported the company since 2019 and continues to play a key role in advancing this major development step.
The full press release can be found in the download.
About 4TEEN4
4TEEN4’s mission is to reverse life-threatening shock and restore organ function with procizumab. This highly specific, first-in-class antibody blocks circulating DPP3, the key pathological driver of mortality in shock. Based on highly encouraging results across preclinical models and initial use in patients, procizumab is now in a Phase 2a study evaluating its potential as a treatment for shock caused by acute cardiovascular and septic events. By targeting the root cause, 4TEEN4 aims to move shock treatment beyond supportive care and improve survival in critically ill patients.
Forther Informations you can find here: www.brandenburg-kapital.de, https://www.4teen4.de